Baxter to cut stake in Baxalta
March 17, 2016Business Services, Sales and Marketing Baxalta, Shares, Stake sale, baxter
Baxalta Inc (NYSE: BXLT) said former parent company Baxter International (NYSE: BAX) is set to cut its stake in the …
Sir Andrew Witty announces decision to step down as CEO of GSK
March 17, 2016Medical Communications, Research and Development Andrew Witty, GSK, GlaxoSmithKline, Neil Woodford, Sir Andrew Witty, Witty, gsk break up, gsk split, retirement, steps down
Sir Andrew Witty has announced his decision to retire from his role as chief executive officer of pharmaceutical giant, GlaxoSmithKline …
GSK’s asthma drug meets primary goal in safety study for children
March 17, 2016Research and Development Advair Diskus, GSK, asthma, drug trial
GlaxoSmithKline (LSE: GSK) said on Thursday its asthma drug met the primary end point in a second study for children. …
Amgen skin cancer drug Imlygic rejected by NICE
March 16, 2016Research and Development Amgen, Imlygic, NICE, melanoma, skin cancer
NICE has rejected Amgen’s drug Imlygic (talimogene laherparepvec) in draft as a treatment for advanced melanoma that has spread and …
Vectura agree £441m merger with Skyepharma
March 16, 2016Manufacturing and Production, Research and Development, Sales and Marketing Skyepharma, UK, biotech, merger, vectura
Vectura (LON: VEC) and Skyepharma (LON: SKP), two UK-based pharma companies, have joined together in a deal worth £441m. The …
Orexigen takes back rights to its weigh management drug from Takeda
March 16, 2016Business Services, Manufacturing and Production, Sales and Marketing Contrave, Orexigen Therapeutics, akeda Pharmaceuticals
Orexigen Therapeutics (Nasdaq: OREX) has taken back the rights to its weight management drug from Japanese pharma giant Takeda Pharmaceuticals …
Vaxon Biotech completes enrollment for mid-stage trial of lung cancer vaccine
March 16, 2016Research and Development, Sales and Marketing NSCLC, immuno-oncology, vaxon biotech
Vaxon Biotech on Wednesday said it has completed the enrollments for mid-stage trials of its vaccine to treat non-small-cell lung …
GSK establish cell and gene therapy collaboration with Miltenyi Biotec
March 16, 2016Medical Communications, Research and Development GSK, GlaxoSmithKline, cell and gene therapy, collaboration, miltenyi biotec
GlaxoSmithKline (NYSE:GSK) has announced a strategic collaboration with Miltenyi Biotec that will see GSK’s expertise in developing cell and gene …
Blueprint Medicines agrees $1 billion-plus deal with Roche for cancer therapy
March 16, 2016Business Services, Research and Development, Sales and Marketing Blueprint Medicines, Deals, Immunokinases, Roche, drug development
Blueprint Medicines Corp (Nasdaq: BPMC) said it has signed an over $1 billion deal with oncology drug giant Roche (SIX: ROG) …
New research supports association between Zika virus and microcephaly
March 16, 2016Medical Communications, Research and Development Lancet, Zika virus, french polynesia, microcephaly, outbreak
Using data from the 2013-14 outbreak of Zika virus in French Polynesia, new research in The Lancet has further supported …
PureTech’s Vedanta Biosciences appoints former Genzyme VP chief scientific officer
March 16, 2016Medical Communications, Research and Development Bruce Roberts, Genzyme, Vedanta Biosciences
Vedanta Biosciences, a company developing therapies designed to modulate the human microbiome, has appointed former Genzyme group vice president, Bruce …
Celator’s shares jump on positive late-stage trials for leukaemia drug
March 16, 2016Business Services, Research and Development, Sales and Marketing Celator Pharmaceuticals, EMA, US FDA, Vyxeos, drug trials, phase III
Shares in trial-stage Celator Pharmaceuticals (Nasdaq: CPXX) soared gaining over four times in value as the company announced late-stage trials …
FDA says benefits outweigh risks in Abbott’s heart stent, Absorb
March 16, 2016Research and Development, Sales and Marketing Abbott, absorb, bioresorbable, coronary artery disease
An independent panel convened by the US Food and Drug Administration (FDA) has unanimously voted that the benefits of Absorb, …
Sanofi to use DiCE Molecules’ platform to boost drug discovery
March 16, 2016Research and Development DiCE Molecules, Sanofi
Sanofi has announced a research partnership with newly-launched DiCE Molecules in which the French pharma giant will use DiCE’s small …
Teva says closing buy of Allergan’s generics biz may take longer
March 16, 2016Business Services, Research and Development, Sales and Marketing Allergan, M&A, MA, Pfizer, Teva
Israel-based Teva Pharmaceuticals Industries (NYSE: TEVA) said its $40.5 billion acquisition of Allergan’s generics business will take longer than expected, …
Lilly changes Alzheimer’s trial endpoint – shares fall
March 16, 2016Research and Development Alzheimer's disease, Eli Lilly, solanezumab
Shares in Eli Lilly fell more than 4% yesterday when it announced it was changing the primary endpoint of a closely-watched …
UPDATE: InVivo Therapeutics prices public offering at $7.50 per share to raise $28 million
March 15, 2016Business Services, Manufacturing and Production, Sales and Marketing InVivo, Share price, Stake sale
InVivo Therapeutics (Nasdaq: NVIV) on Tuesday said it plans to raise about $28 million via a public offering of over …
Valeant cuts 2016 sales, earnings outlook; shares plunge over 47%
March 15, 2016Business Services, Manufacturing and Production, Sales and Marketing Valeant Pharma, fourth quarter, full year, results
Valeant Pharmaceuticals Inc (NYSE: VRX) cut its outlook for the first-quarter of 2016 and posted a loss for the final …
Cellnovo, Roche sign deal to integrate diabetes platforms
March 15, 2016Manufacturing and Production, Sales and Marketing Cellnovo, Roche, diabetes
Cellnovo Group (Paris: CLNV) on Tuesday said it has signed a deal with Swiss drug major Roche (Euronext: ROG) to …
InVivo Therapeutics to sell stake in company; shares drop
March 15, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing InVivo Therapeutics, Stake sale, stocks
InVivo Therapeutics (Nasdaq: NVIV) said it plans to sell an additional stake in the company to raise funds for its ongoing …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
